Thomson Reuters/Verus upgraded shares of VIVUS (NASDAQ:VVUS) from a sell rating to a hold rating in a report released on Monday, Analyst Ratings Net reports. VIVUS (NASDAQ:VVUS) traded up 2.30% during mid-day trading on Monday, hitting $6.23. 2,152,699 shares of the company’s stock traded hands. VIVUS has a 1-year low of $5.63 and a 1-year high of $15.62. VIVUS, Inc. (NASDAQ:VVUS) stock opened at $6.23 in last session, and closed at $6.16, while the day range of VIVUS, Inc. (NASDAQ:VVUS) stock is $6.09 – $6.34. The stock showed a positive weekly performance of 5.12%.
Inovio Pharmaceuticals, Inc. (NYSEMKT:INO) on 4 march closed its previously announced underwritten public offering of 21,810,900 shares of the Company’s common stock. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) stock opened at $3.65 in last session, and closed at $3.52 by losing -0.85%. The 52 week range of $0.49 – $3.95. Company’s market capitalization is $675.69 million.
John C. Martin, the chief executive officer of Gilead Sciences Inc. (NASDAQ:GILD), has become a billionaire on the prospects of a powerful new hepatitis C drug that’s attracting scrutiny from payers and activists over its $1,000 per pill price tag. Gilead Sciences, Inc. (NASDAQ:GILD) stock increased 1.83% and finished the last session at $$82.94. The EPS of the stock remained 1.83. Company’s market capitalization is $127.22 billion.
Shares of MannKind Corp. (NASDAQ:MNKD) saw unusually large options trading activity on Monday. Stock traders acquired 12,443 call options on the stock, Stock Ratings Network reports. This is an increase of approximately 120% compared to the average daily volume of 5,661 call options. MannKind Corporation (NASDAQ:MNKD) stock opened the session at $6.09, and closed the session at $$6.08. The 52 week range of the MannKind Corporation (NASDAQ:MNKD) stock remained $$2.58 – $8.70 and the day range was $$5.96 – $6.19.
Leave a Reply